NCT00637000 - Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Opioid-related Disorders

Interventions

DRUG

Buprenorphine soluble film

Buprenorphine soluble film strips administered sublingually with doses escalated from 12 mg per day up to 24 mg daily for 5 days of total treatment.

DRUG

Buprenorphine/naloxone film strip

Buprenorphine/naloxone soluble film strips administered sublingually with doses escalated from 12 mg buprenorphine/3 mg naloxone to 24 mg buprenorphine /6 mg naloxone daily for 5 days of total treatment.

DRUG

Placebo

Placebo soluble film administered on the same schedule as active treatment to maintain the study blind.

Trial Locations (1)

21224

Johns Hopkins University School of Medicine, Baltimore